Analyser av WntResearch

Analysbevakning

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

WntResearch: Extraordinary general meeting - Redeye

Redeye leaves a short comment on WntResearch’s extraordinary general meeting.

Redeye • 10 Mar 07:24

WntResearch: Undramatic report as expected - Redeye

Redeye comments on WntResearch’s Q4 2024 report. The report was undramatic, which was expected in our view as the focus is on the reverse ac...

Redeye • 28 Feb 07:21

WntResearch: Reverse acquisition of OPSY AB - Redeye

Redeye comments on WntResearch’s conditional reverse acquisition of OPSY AB.

Redeye • 31 Jan 10:10

WntResearch: Q3 cash position aligned with our expectations - Redeye

Redeye provides a note following WntResearch’s Q3 2024 report.

Redeye • 22 Nov 2024 07:23

WntResearch: Comment on company update - Redeye

Redeye provides a comment on WntResearch’s update regarding the work in progress.

Redeye • 10 Oct 2024 08:34

WntResearch: Updated fair value range following initial phase 2 results - Redeye

Redeye provides a longer note following WntResearch’s failed phase 2 study and CEO interview.

Redeye • 18 Sep 2024 07:31

WntResearch: Limited clinical effects from initial phase 2 results - Redeye

Redeye provides a brief comment on WntResearch’s initial phase 2 data.

Redeye • 17 Sep 2024 08:06

WntResearch Q2: An eventful half-year ahead - Redeye

Redeye provides an update following WntResearch’s Q2 report.

Redeye • 23 Aug 2024 09:09

WntResearch: Possible paradigm shift in pre-surgical treatment - Redeye

Redeye initiates coverage of WntResearch, a Swedish biotechnology company specialised in oncology.

Redeye • 13 Jun 2024 08:06

Wntresearch: Bättre utsikter för Foxy-5 - Mangold Insight Analys

WntResearch, som genomför en fas 2-studie med läkemedelskandidaten Foxy-5 för patienter som drabbats av cancer i tjocktarmen, har efter nya ...

Mangold • 05 Jan 2023 08:27